We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Study Of Perennial Allergic Rhinitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00358475
Recruitment Status : Completed
First Posted : July 31, 2006
Last Update Posted : April 15, 2013
Information provided by (Responsible Party):

July 27, 2006
July 31, 2006
April 15, 2013
June 2005
October 2005   (Final data collection date for primary outcome measure)
Adverse events and laboratory blood test
Same as current
Complete list of historical versions of study NCT00358475 on ClinicalTrials.gov Archive Site
Change of nasal symptom score
Same as current
Not Provided
Not Provided
Study Of Perennial Allergic Rhinitis
Study of Perennial Allergic Rhinitis -Long Term Treatment Study-
This study was designed to assess safety of an investigational nasal spray in the treatment of perennial allergic rhinitis. Perennial allergic rhinitis is triggered by house dust, mite and mold etc. Typical symptoms are sneezing, nasal congestion and pruritus and rhinorrhea.
Not Provided
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Rhinitis, Allergic, Seasonal
Drug: GW685698
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
October 2005
October 2005   (Final data collection date for primary outcome measure)

Inclusion criteria:

  • Informed consent.
  • Outpatient.
  • Diagnosis of perennial allergic rhinitis with symptoms.
  • Able to comply with study procedures.

Exclusion criteria:

  • Significant concomitant medical condition.
  • Use of corticosteroids/allergy medications.
  • Laboratory abnormality.
  • Positive pregnancy test.
Sexes Eligible for Study: All
16 Years and older   (Child, Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP